Pipeline lands $1.4M grant

General published Thu, 2014-06-26 15:47

Pipeline Inc. announced it landed a $1.435 million challenge grant from the Ewing Marion Kauffman Foundation to further its entrepreneurial impact in the Kansas City region.

Launched in 2006, Pipeline is a group of regional entrepreneurs that builds high-growth companies though a rigorous yearlong business development program and networking among Pipeline members. It now welcomes businesspeople from Missouri, Kansas and Nebraska.

Pipeline companies as a group generated more than $150 million in revenue and employ 974 people in Kansas, Missouri and Nebraska. In addition, eight Pipeline alumni have cashed in via exits since graduating from the program.

To learn more,  click here.



Metactive Wins First Prize at the Medical Device Entrepreneur's Forum at the ASAIO 60th Annual Conference

Human Health published Tue, 2014-06-24 08:59

OLATHE, Kan.  Metactive Medical, Inc. ("Metactive") announced that it was awarded top prize in a business plan competition hosted by the Medical Device Entrepreneur's Forum, a special session held on June 20, 2014 at the ASAIO 60th Annual Conference in Washington, DC. F. Nicholas Franano, MD, President and Chief Executive Officer of Metactive, presented to a group of experts in medical device development and commercialization, venture capital, reimbursement, and regulatory affairs. Metactive placed first among a selected group of companies with innovative medical devices used for the treatment or diagnosis of disease.


"The role that ASAIO has played in bringing together a diverse group of creative and entrepreneurial scientists, engineers, clinicians, and industry representatives has been a critical factor in the development of a wide range of life saving technologies that we rely on today, including hemodialysis machines, ventricular assist devices, and extracorporeal membrane oxygenators, among many others," said Dr. Franano. "I know of no better place where medical device inventors and innovators can find fellow travelers, collaborators and friends. I'm honored that Metactive was recognized by this group."



ASAIO (formerly known as the American Society for Artificial Internal Organs) is a premier society founded in 1955 for physicians, scientists, engineers, and entrepreneurs dedicated to the continually evolving fields of artificial organs, medical devices, and tissue engineering. For more information visit www.asaio.com.


About Metactive Medical

Metactive is developing novel endovascular medical devices for the treatment of neurovascular and peripheral vascular diseases. Metactive's first products enable precise and immediate occlusion and rapid sealing of cerebral aneurysms and other target vessel segments using an over-the-wire microcatheter platform. For more information, please visit www.metactivemedical.com.



Aratana Therapeutics Initiates and Doses First Patient in Market Development Studies of AT-005 for Treating Canine T-cell Lymphoma

Animal Health published Fri, 2014-06-20 11:20

KANSAS CITY, Kan., Aratana Therapeutics, Inc., a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it is currently enrolling patients in two nationwide clinical trials to evaluate its monoclonal antibody for canine T-cell lymphoma, AT-005, which is conditionally licensed by the USDA to aid in the treatment of dogs with lymphoma.

These studies are not required by the USDA to obtain a full product license for AT-005, for which it is currently under review. They were designed by veterinary oncologists to evaluate AT-005 under real practice conditions, which will help Aratana and oncologists understand the clinical value of AT-005 once it is fully licensed by the USDA, which is anticipated to be in 2015. Specifically, the studies will evaluate AT-005 in combination with two different chemotherapy regimens used to treat dogs diagnosed with intermediate- to high-grade peripheral T-cell lymphoma. 

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "Aratana is committed to demonstrating the full clinical potential of our novel pet biologics, which may offer veterinarians a new paradigm for treating lymphoma in dogs. In addition to the positive safety and efficacy data upon which the USDA based our product licenses for our canine lymphoma monoclonal antibodies, we believe the results of these two market development studies will be instrumental for demonstrating the potential benefit of adding a biologic to standard chemotherapy. Similar regimens have had meaningful impact on patient outcomes in human drug development, and we believe our ability to demonstrate a similar effect for AT-005 will facilitate its adoption by veterinarians and pet owners."

The studies are being conducted in coordination with Animal Clinical Investigation, LLC (ACI).

This study is currently enrolling patients.  For more information, please visit http://www.animalci.com/trials/t-lab .

Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes more than fifteen therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.


IGXBio receives FDA approval to move forward with GenePro® clinical trials

Human Health published Tue, 2014-06-17 17:29

Lenexa, KS – IGXBio, Inc. has received approval from U.S. Food and Drug Administration (FDA) to begin human clinical trials of GenePro®, a DNA-based HIV vaccine.

Jim Laufenberg, Co-Founder and CEO of IGXBio stated, “This is a very exciting time for the company, and achieving this milestone allows us to proceed with first in-man studies in HIV positive individuals”.
IGXBio, formerly known as Immunogenetix Therapeutics, has also received angel investment from the Mid-America Angels and funding from the State of Kansas. To date, the company has received $4,625,000 in capital funding to develop its DNA therapies. In addition, the National Institutes of Health has provided $21,000,000 in grants to the development of GenePro®.

About IGXBio
IGXBio, Inc. is a clinical-stage biotechnology company developing DNA therapies for the treatment of viral infections with a focus on HIV. The company's proprietary lead candidate, GenePro®, has published efficacy studies in non-human primates with promising results. The incidence for HIV/AIDS is estimated at 1.1 million in the U.S. and growing. Due to drug resistance developing in the use of current antiretroviral drug therapy, along with an increase in serious adverse effects, there is a large demand for immune modulating drugs such as GenePro®. For more information please visit: IGXBio.com.



Demo Day a big success

Human Health published Tue, 2014-06-17 12:03

Demo Day was held last week in the Kauffman Center for the Performing Arts for the 10 companies that completed the Sprint Mobile Health Accelerator. A representative from each company gave a 5-7 minute pitch to a roomful of investors.

All the efforts paid off as each of the CEOs drew a crowd of investors after the event, said Keith Harrington, who was in that crowd for the Kansas Bioscience Authority.

Harrington had met each of the companies’ teams three months ago and mentored a few as part of the program. All of them made “unbelievable progress,” for example, in their businesses’ focus and strategies for making money, he said.

Investor backing was the most hoped-for payoff Thursday, though no one was announcing deals immediately or even how much money they were asking for.

For many, the range probably was between $500,000 and $1.5 million, though a few seemed far enough along to Harrington that they could attract venture capital backing of perhaps $3 million or even $5 million.

- Mark Davis, The Kansas City Star
Read more here: http://www.kansascity.com/news/business/technology/article564748/Businesses-grow-up-fast-inside-accelerator.html#storylink=cpy



Aratana Therapeutics licenses new stem cell therapy for arthritis in dogs

Animal Health published Fri, 2014-06-13 15:19

Aratana Therapeutics Inc. has licensed a new stem cell therapy that it plans to develop to treat osteoarthritis in dogs.

The agreement grants the Kansas City, Kan., animal health company the exclusive rights to commercialize the therapy from Vet-Stem Inc., a California veterinary regenerative medicine company.

Vet-Stem, according to a release, pioneered a process in which fat tissue is harvested from a patient before stem cells are isolated and then reintroduced back into that patient. The company also has developed a technology in which a single donor sample can be used to generate doses that can be stored and used to treat a number of patients.

Aratana licensed that therapy, which it will test for safety and efficacy in treating osteoarthritis in dogs.

"As we continue to build our pipeline, we have made a clear strategic investment in the high-need area of pain management for our pets," Aratana CEO Steven St. Peter said in a statement. "We therefore are pleased to expand our pain franchise further by adding an allogeneic, regenerative cell therapy product, which in addition to its aim of reducing the pain of osteoarthritis, has the potential to impact the progression of the disease, and to promote tissue regeneration. We will examine this phenomenon in planned studies, which could result in product labeling that specifies disease-modifying properties."


- The Kansas City Business Journal



Demo day arrives for 10 budding businesses at Sprint Mobile Health Accelerator

General published Thu, 2014-06-12 12:51

The CEOs of 10 young companies will pitch investors on their young companies this evening at the Kauffman Center for the Performing Arts.

Each CEO gets five minutes to pitch a group of vetted investors at the Kauffman Center for the Performing Arts this evening. If anyone has a case of the nerves, Wednesday’s rehearsal may have helped.

“I expect it to be really intense, focused, and to result in probably some deals getting done,” said Keith Harrington, with the Kansas Bioscience Authority and one of the investors. “We are thinking about a couple of these companies right now.”

- The Kansas City Star


Aratana Therapeutics Reports First Quarter 2014 Results

Animal Health published Tue, 2014-06-03 16:21

KANSAS CITY, Kan., -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced its first quarter 2014 financial results.

"Aratana continues to advance its deep pipeline of therapeutics focused on treating serious diseases in pets," stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. "We are establishing ourselves as a leader in the rapidly evolving pet therapeutics industry."


Click here to view report.